



UNIVERSITAT DE
BARCELONA

FG-AI4H-Q-031 Attachment 1



FUTURE-AI: International Guidelines for Trustworthy & Deployable AI in Healthcare

Karim Lekadir

University of Barcelona

Artificial Intelligence in Medicine Lab (BCN-AIM)



Part 1-

Do We Need Guidelines for Trustworthy Medical AI?



Medical AI in Research




Artificial intelligence papers in biomedical research

Source: PubMed (2000 – 2021)

2016: **8,551** papers

2021: **44,027** papers





Medical AI in Media



BBC Sign in Home News Sport Reel Worklife Travel

NEWS

Home Coronavirus Climate Video World UK Business Tech Science Stories Entertainment & Arts


Health Coronavirus

AI 'outperforms' doctors diagnosing breast cancer



Fergus Walsh
Medical correspondent
@BBCFergusWalsh

© 2 January 2020



News Opinion Sport Culture Lifestyle

Coronavirus World UK Environment Science Global development Football Tech Business Obituaries

Artificial intelligence

The New York Times

Pandemic > Covid-19 Updates Coronavirus Map and Cases Track State Mask Mandates Analysis

A.I. Versus the Coronavirus

A new consortium of top scientists will be able to use some of the world's most advanced supercomputers to look for solutions.



AI system as good as experts at recognising skin cancers, say researchers

Deep learning-based system could be further developed for smartphones, increasing access to screening and aiding early detection of cancers





FDA-Cleared AI



AI CENTRAL DATA SCIENCE INSTITUTE™ AMERICAN COLLEGE OF RADIOLOGY [ACR.org](#)

Home Data Science Institute Editorial Board Email DSI

Welcome to ACR Data Science Institute AI Central. This site is intended to provide easy-to-access, detailed information regarding FDA cleared AI medical products that are related to radiology and other imaging domains. Our [editorial board](#) and staff are continuously reviewing data from FDA public facing documents, vendor information and physician user feedback to provide you with up-to-date information that will help you to make appropriate purchasing decisions. Check back regularly to see which new algorithms are available and have been added to the list. Send information on AI algorithms that are not listed and report missing information to DSI@acr.org.

Best,
Keith J. Dreyer, DO, PhD, FACR, FSIIM
Chairman of Editorial Board, AI Central Editorial

Board members: Christoph Wald, MD, PhD, MBA, FACR - Bibb Allen Jr., MD, FACR - Sheela Agarwal, MD, MBA - Judy W. Gichoya, MD, MS - Jay Patti, MD

210 AI tools !

Free Text Search Company Type Finding Body Area Subspeciality Modality Date Cleared

↓ Date Cleared	Product	Company	Type	Finding	Body Area	Subspeciality	Modality	Filters
2021-10-29	Critical Care Suite with End...	GE Medical Systems	Image Processing/Quantification	Lines and tubes (chest)	Chest	Chest Imaging	XRAY	
2021-10-22	FlightPlan for Liver	GE Medical Systems	Image Processing/Quantification	Liver display	Liver	Abdominal Imag...	XRAY	
2021-10-21	StrokeSENS LVO	Circle Cardiovascular Ima...	CADt	Intracranial large vessel ...	Brain	Neuroradiology	CT	
2021-10-14	Brainance MD	Advantis Medical Imaging...	Image Processing/Quantification	Brain anatomy	Brain	Neuroradiology	MR	
2021-10-12	VBrain-OAR	Vysioneer Inc.	Image Processing/Quantification	Brain anatomy	Brain	Neuroradiology	MR	
2021-09-15	HealthCCSng	Zebra Medical Vision Ltd.	Image Processing/Quantification	Calcified plaques	Coronary A...	Cardiac Imaging	CT	

Cleared but not approved

<https://aicentral.acrdsi.org>

Low-Risk AI







Image segmentation:

- ✓ Clinicians can verify and correction the segmentations
- ✓ Limited risk for patient harm
- ✓ Enormous gain in productivity



FDA-Cleared AI





Would You Trust an **AI Tool** that Decides on
Your Diagnosis and/or Treatment?



Would You Trust a **New Vaccine** Developed
Against a New Infectious Disease?




Covid-19 Vaccines



Trust about 6 months after vaccination started

Which of these COVID-19 vaccines do you trust the most? (%) **Asked only of respondents who have not yet received the vaccine





Would **You** Trust an AI Tool that Decides on
Your Diagnosis and/or Treatment?



You

The physician

The social carer

The health centre

The data protection officer

The health authorities

Your fellow citizens

Your insurance



Part 2-

Success Story:

FAIR Guidelines for Data Management

Guidelines

- What is a guideline (Oxford Languages):
 - A general rule
 - Principle
 - Piece of advice.
- Other synonyms:
 - Best practice
 - Code of practice.





FAIR Guidelines



SCIENTIFIC DATA

Amended: Addendum

OPEN

Comment: The FAIR Guiding Principles for scientific data management and stewardship

SUBJECT CATEGORIES

- » Research data
- » Publication characteristics


Mark D. Wilkinson *et al.*[#]

Received: 10 December 2015

Accepted: 12 February 2016

Published: 15 March 2016

There is an urgent need to improve the infrastructure supporting the reuse of scholarly data. A diverse set of stakeholders—representing academia, industry, funding agencies, and scholarly publishers—have come together to design and jointly endorse a concise and measurable set of principles that we refer to as the FAIR Data Principles. The intent is that these may act as a guideline for those wishing to enhance the reusability of their data holdings. Distinct from peer initiatives that focus on the human scholar, the FAIR Principles put specific emphasis on enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse by individuals. This Comment is the first formal publication of the FAIR Principles, and includes the rationale behind them, and some exemplar implementations in the community.



>8,000 citations



FAIR Guidelines



Box 2 | The FAIR Guiding Principles

To be Findable:

- F1. (meta)data are assigned a globally unique and persistent identifier
- F2. data are described with rich metadata (defined by R1 below)
- F3. metadata clearly and explicitly include the identifier of the data it describes
- F4. (meta)data are registered or indexed in a searchable resource

To be Accessible:

- A1. (meta)data are retrievable by their identifier using a standardized communications protocol
 - A1.1 the protocol is open, free, and universally implementable
 - A1.2 the protocol allows for an authentication and authorization procedure, where necessary
- A2. metadata are accessible, even when the data are no longer available

To be Interoperable:

- I1. (meta)data use a formal, accessible, shared, and broadly applicable language for knowledge representation.
- I2. (meta)data use vocabularies that follow FAIR principles
- I3. (meta)data include qualified references to other (meta)data

To be Reusable:

- R1. meta(data) are richly described with a plurality of accurate and relevant attributes
 - R1.1. (meta)data are released with a clear and accessible data usage license
 - R1.2. (meta)data are associated with detailed provenance
 - R1.3. (meta)data meet domain-relevant community standards



FAIR Guidelines



[FAIR Principles](#) [Implementation Networks](#) [News](#) [Events](#) [Resources](#) [About GO FAIR](#) [Q](#)

F1: (Meta) data are assigned globally unique and persistent identifiers

www.go-fair.org

Example services that supply globally unique and persistent identifiers

- Identifiers.org provides resolvable identifiers in the form of URIs and CURIEs: <http://identifiers.org>
- Universally unique identifier: https://en.wikipedia.org/wiki/Universally_unique_identifier
- Persistent URLs: <http://www.purlz.org>
- Digital Object Identifier: <http://www.doi.org>
- Archival Resource Key: <https://escholarship.org/uc/item/9p9863nc>
- Research Resource Identifiers: <https://scicrunch.org/resources>

FAIR Impact

The image shows the cover of a report titled "Cost of not having FAIR research data". At the top, there is the European Commission logo. The title is in bold black text. Below the title, it says "Cost-Benefit analysis for FAIR research data". A large red box highlights the figure "10.2 billion Euros". At the bottom left, it says "Written by PwC EU Services March - 2018". At the bottom right, there is a small blue box with the text "Research and Innovation".

Cost of not having FAIR research data

Cost-Benefit analysis for FAIR research data

10.2 billion Euros

Written by PwC EU Services
March - 2018

Research and Innovation

Indicators

1. Time spent
2. Cost of storage
3. Licence costs
4. Research retraction
5. Double funding
6. Cross-fertilization
7. Potential economic growth (as % of GDP)



FAIR Impact



EU CALL: Clinical validation of AI solutions for treatment and care

TOPIC ID: HLTH-2021-DISEASE-04-04

“Proposals have to ensure that resulting data comply with the FAIR^[2] principles.”

^[2] FAIR data are data, which meet principles of findability, accessibility, interoperability, and reusability.




EUROPEAN COMMISSION
Directorate-General for Research & Innovation

H2020 Programme

Guidelines on
FAIR Data Management in Horizon 2020

FAIR Strengths



- ✓ Compact (4 principles, 15 items)
- ✓ Agreed upon internationally (sort of)
- ✓ Complements data regulations on privacy and security
- ✓ Backed by authorities



Part 3-

FUTURE-AI Guidelines



FUTURE-AI Promoters






FUTURE-AI Approach



Similar to FAIR:

Compact, focused on general rules





ALTAI Checklist



Apply to AI in general
~140 questions





FG-AI4H Good Practices



INTERNATIONAL TELECOMMUNICATION UNION

**TELECOMMUNICATION
STANDARDIZATION SECTOR**

STUDY PERIOD 2017-2020

FG-AI4H-N-031

ITU-T Focus Group on AI for Health

Original: English

WG(s): Plenary

E-meeting, 15-17 February 2022

DOCUMENT

Source: Editors DEL2.2

Title: DEL2.2 Update: Good practices for health applications of machine learning:
Considerations for manufacturers and regulators



Reporting Guidelines







BMJ Open Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence

Gary S Collins ^{1,2} Paula Dhiman ^{1,2} Constanza L Andaur Navarro ³
Jie Ma ¹ Lotty Hooft,^{3,4} Johannes B Reitsma,³ Patricia Logullo ^{1,2}
Andrew L Beam ^{5,6} Lily Peng,⁷ Ben Van Calster ^{8,9,10}
Maarten van Smeden ³ Richard D Riley ¹¹ Karel GM Moons^{3,4}



OPEN Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension

Samantha Cruz Rivera^{1,2,3}, Xiaoxuan Liu ^{3,4,5,6,7}, An-Wen Chan⁸, Alastair K. Denniston ^{1,3,4,5,6,9} 
Melanie J. Calvert ^{1,2,3,6,10,11,12}, The SPIRIT-AI and CONSORT-AI Working Group*, SPIRIT-AI and CONSORT-AI Steering Group and SPIRIT-AI and CONSORT-AI Consensus Group

Radiology: Artificial Intelligence



Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers

John Mongan, MD, PhD • Linda Moy, MD • Charles E. Kahn, Jr, MD, MS

From the Department of Radiology and Biomedical Imaging, University of California–San Francisco, San Francisco, Calif (J.M.); Department of Radiology and Center for Advanced Imaging Innovation and Research, New York University School of Medicine, New York, NY (L.M.); and Department of Radiology, University of Pennsylvania, 3400 Spruce St, 1 Silverstein, Philadelphia, PA 19104 (C.E.K.). Received March 4, 2020; revision requested March 5; accepted March 5. Address correspondence to C.E.K. (e-mail: ckahn@rsna.org).



Evaluation Guidelines



JAMIA Open, 3(3), 2020, 326–331
doi: 10.1093/jamiaopen/ooaa033
Advance Access Publication Date: 8 September 2020
Perspective



Open access

Review

BMJ Health & Care Informatics

Evaluation framework to guide implementation of AI systems into healthcare settings

Perspective

Evaluating artificial intelligence in medicine: phases of clinical research

Yoonyoung Park¹, Gretchen Purcell Jackson^{2,3}, Morgan A. Foreman¹, Daniel Gruen¹, Jianying Hu⁴ and Amar K. Das¹

Sandeep Reddy ¹, Wendy Rogers,² Ville-Petteri Makinen,³ Enrico Coiera ⁴, Pieta Brown,⁵ Markus Wenzel,⁶ Eva Weicken,⁶ Saba Ansari,⁷ Piyush Mathur ⁸, Aaron Casey,³ Blair Kelly⁷



Regulatory Frameworks for Development and Evaluation of Artificial Intelligence–Based Diagnostic Imaging Algorithms: Summary and Recommendations

David B. Larson, MD, MBA^a, Hugh Harvey, MBBS^b, Daniel L. Rubin, MD, MS^c, Neville Irani, MD^d, Justin R. Tse, MD^e, Curtis P. Langlotz, MD, PhD^f



FUTURE-AI Guidelines



Summarise current knowledge into FUTURE-AI guidelines

- Compact as FAIR → 6 principles
- Focus on general rules → 30 rules
- Through consensus → 95+ international experts
- Inter-disciplinary → AI scientists, clinicians, ethics & legal experts, social scientists, regulators, etc



Literature Review



Robustness, safety, security, Fairness
transparency, Traceability, accountability
generalisability, Explainability, Usability
responsible AI



Literature Review



Robustness, safety, security, **F**airness
transparency, Traceability, accountability
generalisability, **E**xplainability, **U**sability
responsible AI

FEU



Literature Review



Robustness, safety, security, **F**airness

transparency, **T**raceability, accountability

generalisability, **E**xplainability, **U**sability

responsible AI

FEURT

Literature Review

Robustness, safety, security, **F**airness

transparency, **T**raceability, accountability

Universality, **E**xplainability, **U**sability

responsible AI

FEURTU



Final Acronym

Robustness, safety, security, **F**airness

transparency, **T**raceability, accountability

Universality, **E**xplainability, **U**sability

responsible AI

FEURTU → FUTURE

Medical AI Shall Be:

F







U

T

U

R

E

FAIR	UNIVERSAL	TRACEABLE	USABLE	ROBUST	EXPLAINABLE
					

Methodology

(1) Create working groups for each guiding principle



(2) Review literature then propose initial guidelines



(3) Organise a survey with 80+ international experts



(4) Gather feedback on guidelines & disagreements



(5) Obtain a final list of 30 consensus guidelines



Consortium



www.future-ai.eu

karim.lekadir@ub.edu



Fairness



1. Define sources of bias (at the design phase)
2. Collect data according to sources of bias (when possible)
3. Evaluate bias (when data permits it)
4. Mitigate bias (if bias is identified)



Universality



1. Define clinical settings (and variations across settings)
2. Use proven standards (clinical, technical, etc)
3. Perform external validation (with external data, sites, evaluators)
4. Apply generalisation measures (if needed)



Traceability



1. Define requirements for traceability (what to trace, when, how, by whom)
2. Provide documentation (general, technical, scientific)
3. Implement tools for monitoring (quality control, periodic evaluations, model updates, logging)
4. Implement human oversight and governance (quality control, decision over-rule, tool management)



Usability



1. Define intended use and user requirements
2. Provide training (materials and activities)
3. Evaluate usability (with diverse end-users)
4. Evaluate utility & safety (in real-world practice)



Robustness



1. Define sources of data variations
2. Train with representative data
3. Test robustness (against real-world variations)
4. Apply robustness measures (if needed)



Explainability



1. Define need, goals and approaches for explainability
2. Test explainability (with end-users)
3. Estimate uncertainty (calibrated)



General



1. Engage inter-disciplinary stakeholders
2. Implement measures for data protection
3. Select appropriate evaluation metrics
4. Comply with medical AI regulations
5. Implement security measures against attacks
6. Investigate and address ethical issues
7. Investigate and address social issues



FUTURE-AI Paper



FUTURE-AI: International consensus guidelines for trustworthy and deployable artificial intelligence in healthcare

Abstract:

Despite major advances in the field of medical artificial intelligence (AI) over the years, the deployment and adoption of AI technologies remain limited in real-world clinical practice. In recent years, concerns have been raised on the technical, clinical, ethical and legal risks associated with medical AI. To increase adoption in the real world, it is essential that medical AI tools are trusted and accepted by patients, clinicians, health organisations and authorities. This paper addresses an important gap in the field of medical AI, by delivering the FUTURE-AI framework as the very first international, consensus guidelines for trustworthy and deployable AI in healthcare. We established a concise, yet actionable list of 30 guidelines organised according to six guiding principles of trustworthy AI, *i.e.* Fairness, Universality, Traceability, Usability, Robustness and Explainability. We employed an iterative process based on a modified Delphi approach, with a large-scale multi-stakeholder, multi-disciplinary, multi-society and multi-national consultation that involved a consortium of over 90 inter-disciplinary experts from all continents. The derived guidelines are holistic and cover technical, clinical, legal and socio-ethical dimensions of trustworthy AI, as well as the entire lifecycle of medical AI, from design, development and validation to regulation, deployment, and monitoring. The FUTURE-AI framework is intended to guide AI developers in the process of building medical AI tools that will be deployed, adopted and used in real-world practice. Furthermore, researchers are encouraged to take the guidelines into account in proof-of-concept stages to facilitate future translation towards clinical practice of medical AI.



FUTURE-AI



FUTURE^{AI}

[HOME](#) [FUTURE-AI GUIDELINES](#) [ASSESSMENT CHECKLIST](#) [CURRENT PROJECTS](#) [CONTACT US](#)

FUTURE-AI: Best practices for trustworthy AI in medicine

FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation and deployment of trustworthy AI solutions in medicine and healthcare based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness and Explainability.

www.future-ai.eu

karim.lekadir@ub.edu



Next Steps



- Integrate feedback from FG-AI4H members
- Submit the paper as a contribution to the FG-AI4H
- Compare the FUTURE-AI and FG-AI4H deliverables, identify commonalities, mismatches and complementarities
- Discuss further (e.g. March meeting)



Funding



EuCanImage (2020-2024)
Grant # 952103

RadioVal (2022-2026)
Grant # 101057699



www.future-ai.eu

karim.lekadir@ub.edu



Acknowledgment



www.future-ai.eu

karim.lekadir@ub.edu